Clinical Trial

TAD After Chemotherapy in Locally Advanced Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 10, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-28; most recent amendment 2025-09-08.
Trial Details
NCT Number NCT05763641
Lead Sponsor Hospital Universitari de Bellvitge
Conditions Sentinel Lymph Node, Breast Cancer, Locally Advanced
Enrollment 162 participants
Start Date 2021-02-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-10